Canada Markets closed

Valneva SE (VLA.VI)

Vienna - Vienna Delayed Price. Currency in EUR
Add to watchlist
15.24+0.49 (+3.32%)
At close: 05:32PM CET
Full screen
Previous Close14.75
Bid0.00 x 50000
Ask0.00 x 81200
Day's Range14.84 - 15.56
52 Week Range2.06 - 15.56
Avg. Volume14,123
Market Cap1.373B
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-1.35
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine Candidate

    Saint-Herblain (France), January 25, 2022 – Valneva SE, a specialty vaccine company, today announced the start of booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is intended to provide both homologous and first heterologous booster data to complement previous positive Phase 1/2 booster results. The data are not intended for the initial regulatory approval process which the Company expects to finalize in the coming weeks. The trial ex

  • Zacks

    Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant

    Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.

  • GlobeNewswire

    Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant

    Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant (B.1.1.529 lineage) 100% of tested serum samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant Saint Herblain (France), January 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced results from an initial laborat